CARA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	301 495
Average Volume	660 382
Market Cap	37.71M
EPS	$0 ( 2024-03-04 )
Next earnings date	( $-0.380 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.320
ATR14	$0.00300 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Goncalves Joana	Sell	2 753	Common Stock
2024-04-05	Terrillion Scott	Sell	2 753	Common Stock
2024-02-29	Terrillion Scott	Sell	3 293	Common Stock
2024-02-29	Posner Christopher	Sell	5 834	Common Stock
2024-02-29	Goncalves Joana	Sell	3 293	Common Stock

INSIDER POWER
72.01
Last 96 transactions
Buy: 1 992 546 \| Sell: 375 720

Volume Correlation

Long: -0.01 (neutral)

Short: -0.65 (weak negative)

Signal:(35.693) Neutral

Cara Therapeutics Inc Correlation

10 Most Positive Correlations
AHCO	0.982
MDRX	0.978
TTEC	0.974
TUEM	0.973
UPLD	0.972
APTX	0.97
SSP	0.969
OLPX	0.964
MICS	0.963
VERU	0.961

10 Most Negative Correlations
CPTA	-0.959
XLRN	-0.958
FLMN	-0.955
ZGNX	-0.953
TIG	-0.952
ITI	-0.948
PPYAU	-0.948
RAM	-0.946
GPACU	-0.942
KTCC	-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cara Therapeutics Inc Correlation - Currency/Commodity

0.70
( moderate )

0.11
( neutral )

0.00
( neutral )

-0.61
( weak negative )

Cara Therapeutics Inc Financials

Annual	2023
Revenue:	$20.97M
Gross Profit:	$14.54M (69.32 %)
EPS:	$-2.19

Q4	2023
Revenue:	$3.00M
Gross Profit:	$2.31M (77.03 %)
EPS:	$-0.590

Q3	2023
Revenue:	$4.87M
Gross Profit:	$3.31M (67.98 %)
EPS:	$-0.520

Q2	2023
Revenue:	$6.93M
Gross Profit:	$5.52M (79.55 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Cara Therapeutics Inc

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.